IRF5 regulates lung macrophages M2 polarization during severe acute pancreatitisin vitro

Abstract

AIMTo investigate the role of interferon regulatory factor 5 (IRF5) in reversing polarization of lung macrophages during severe acute pancreatitis (SAP) in vitro.METHODSA mouse SAP model was established by intraperitoneal (ip) injections of 20 μg/kg body weight caerulein. Pathological changes in the lung were observed by hematoxylin and eosin staining. Lung macrophages were isolated from bronchoalveolar lavage fluid. The quantity and purity of lung macrophages were detected by fluorescence-activated cell sorting and evaluated by real-time polymerase chain reaction (RT-PCR). They were treated with IL-4/IRF5 specific siRNA (IRF5 siRNA) to reverse their polarization and were evaluated by detecting markers expression of M1/M2 using RT-PCR.RESULTSSAP associated acute lung injury (ALI) was induced successfully by ip injections of caerulein, which was confirmed by histopathology. Lung macrophages expressed high levels of IRF5 as M1 phenotype during the early acute pancreatitis stages. Reduction of IRF5 expression by IRF5 siRNA reversed the action of macrophages from M1 to M2 phenotype in vitro. The expressions of M1 markers, including IRF5 (S + IRF5 siRNA vs S + PBS, 0.013 ± 0.01 vs 0.054 ± 0.047, P < 0.01), TNF-α (S + IRF5 siRNA vs S + PBS, 0.0003 ± 0.0002 vs 0.019 ± 0.018, P < 0.001), iNOS (S + IRF5 siRNA vs S + PBS, 0.0003 ± 0.0002 vs 0.026 ± 0.018, P < 0.001) and IL-12 (S + IRF5 siRNA vs S + PBS, 0.000005 ± 0.00004 vs 0.024 ± 0.016, P < 0.001), were decreased. In contrast, the expressions of M2 markers, including IL-10 (S + IRF5 siRNA vs S + PBS, 0.060 ± 0.055 vs 0.0230 ± 0.018, P < 0.01) and Arg-1 (S + IRF5 siRNA vs S + PBS, 0.910 ± 0.788 vs 0.0036 ± 0.0025, P < 0.001), were increased. IRF5 siRNA could reverse the lung macrophage polarization more effectively than IL-4.CONCLUSIONTreatment with IRF5 siRNA can reverse the pancreatitis-induced activation of lung macrophages from M1 phenotype to M2 phenotype in SAP associated with ALI.

Inhibition of IRF5 hyperactivation protects from lupus onset and severity

“…Identification of IRF5 as a global risk factor for autoimmune and inflammatory diseases (5,11,20,(36)(37)(38), coupled with its increased activation in the blood of patients with SLE, indicates that IRF5 is an attractive target for therapeutic inhibition. While C-terminal phosphorylation and dimerization represent steps amenable to inhibition (39), neither has been definitively shown to be an absolute requirement for nuclear translocation (35).…”

The Role of Macrophages in the Pathogenesis of ALI/ARDS

“…The transcription factor IRF5 is another major regulator of proinflammatory M1 macrophage polarization. It is generally involved in the process of the downstream TLR-myeloid differentiation factor 88 signaling pathway, inducing proinflammatory cytokines and repressing transcription of anti-inflammatory cytokines such as IL-10 [ 56 ]. In a study by Qin et al [ 57 ], IRF5 expression was increased in the absence of SOCS3, which promoted M1 macrophage polarization.…”

Therapeutic Targeting of IRFs: Pathway-Dependence or Structure-Based?

“…These macrophages were polarized toward the M2 phenotype after treatment with IRF5 siRNA in vitro . Moreover, in vivo , treatment with IRF5 siRNA reversed the pancreatitis-induced activation of lung macrophages from M1 phenotype to M2 phenotype ( 134 ). Last, selective suppression of IRF5 in microglia cells using gene therapy with homing peptide-siRNA-IRF5 complexes in a mouse model of neuropathic pain resulted in a significant reduction in neuropathic pain ( 91 ).…”